支付方主导的吸入性糖皮质激素更换对肺功能的影响
该回顾性图表综述纳入肯塔基州某医疗补助支付方2016年8月取消倍氯米松MDI覆盖、改用莫米松MDI或DPI后,6-18岁哮喘患儿在更换前后各半年就诊的肺功能数据。继续使用MDI者无显著变化,7例停用ICS。结论提示支付方处方集更换吸入装置可能对患儿肺功能产生不利影响。
要点
- 支付方取消倍氯米松MDI覆盖、改用莫米松后,从MDI换用DPI的患儿FEV1和FEF25%-75%均显著下降。
- 继续使用MDI的患儿肺功能无显著变化,提示装置类型而非药物本身可能影响结果。
- 7例患儿停用吸入性糖皮质激素,处方集变更可能影响治疗持续性。
核心结论
- 支付方处方集变更导致患儿换用不同吸入装置,可能对儿童哮喘肺功能产生不利影响,肺功能或可作为整体哮喘控制的替代指标。
研究设计与样本
- 回顾性图表综述,纳入肯塔基州某医疗补助支付方覆盖的6-18岁哮喘患儿,比较2016年2-7月(变更前)与2017年2-7月(变更后)就诊的肺功能数据,采用配对Student t检验。
主要发现
- 从MDI换用DPI的24例患儿FEV1中位预计值从98.5%降至91%(P=.013),FEF25%-75%从89.5%预计值降至76%预计值(P=.041)。
- 继续使用MDI的患儿肺功能无显著变化,7例患儿停用吸入性糖皮质激素治疗。
临床怎么用
- 处方集变更涉及吸入装置转换时,应评估患儿使用DPI的能力并提供及时教育,避免肺功能下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the impact of a payor-initiated formulary change in inhaled corticosteroid coverage on lung function in patients with asthma and on provider prescribing practices. This formulary change, undertaken in August 2016 by a Medicaid payor in Kentucky, eliminated coverage of beclomethasone dipropionate, a metered dose inhaler (MDI), in favor of mometasone furoate, available as MDI and dry powder inhaler (DPI). STUDY DESIGN: A retrospective chart review was conducted on children with asthma ages 6-18 years covered by the relevant payor from a university-based pediatric practice who were seen before the formulary change (February to July 2016) and after (February to July 2017). Spirometry data from each visit was compared using the paired Student t test. RESULTS: Fifty-eight patients were identified who were initially on beclomethasone dipropionate and had spirometry available at both visits. Those who switched from an MDI to a DPI (n = 24) saw a decline in median predicted forced expiratory volume in 1 second from 98.5% to 91% (P = .013). A decline was also seen in forced expiratory flow at 25%-75%, from 89.5% predicted to 76% predicted (P = .041). No significant changes were observed in children remaining on an MDI. Seven patients discontinued inhaled corticosteroid therapy. CONCLUSIONS: This study suggests insurance formulary changes leading to use of a different inhaler device may have a detrimental impact on pediatric lung function, which may be a surrogate measure for overall asthma control. This could be due to a lack of adequate timely educational intervention as well as the inability of some children to use DPIs.
引用
- Bickel S, Morton R, O'Hagan A, et al. Impact of Payor-Initiated Switching of Inhaled Corticosteroids on Lung Function. J Pediatr. 2021. PMID: 33711287. doi:10.1016/j.jpeds.2021.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。